Back

LZTR1 inactivation promotes MAPK/ ERK pathway activation in glioblastoma by stabilizing oncoprotein RIT1

Wang, Y.; Zhang, J.; Zhang, P.; Zhao, Z.; Huang, Q.; Yun, D.; Chen, J.; Chen, H.; Wang, C.; Lu, D.

2020-03-15 cancer biology
10.1101/2020.03.14.989954 bioRxiv
Show abstract

Large-scale sequencing studies on glioblastoma have identified numerous genetic alterations. Leucine-zipper-like transcription regulator 1 (LZTR1) is inactivated by non-synonymous mutations and copy number losses, suggesting that it is a tumor suppressor in glioblastoma. However, how LZTR1 mutations contribute to glioblastoma pathogenesis remains poorly understood. Here, we revealed that LZTR1, as an adaptor of the CUL3 E3 ubiquitin ligase complex, recognizes and triggers ubiquitin-dependent degradation of oncoprotein RIT1, a RAS-like GTPase. Wild-type LZTR1 suppresses glioblastoma cell proliferation and migration by inactivating the MAPK/ERK signaling pathway in a RIT1-dependent manner. However, the effects were abrogated by the glioblastoma-associated LZTR1 mutations. Our findings revealed the underlying molecular mechanism of LZTR1 mutations-driven glioblastoma, and provide novel therapeutic target for LZTR1 mutations-driven glioblastoma.

Matching journals

The top 16 journals account for 50% of the predicted probability mass.

1
eLife
● 5828 papers in training set
Top 11%
9.6%
Similar papers in this journal
2
Oncogene
○ 85 papers in training set
Top 0.4%
4.8%
Similar papers in this journal
3
Acta Neuropathologica Communications
○ 89 papers in training set
Top 0.6%
3.5%
Similar papers in this journal
4
Journal of Biological Chemistry
○ 690 papers in training set
Top 3%
3.2%
Similar papers in this journal
5
Neoplasia
○ 23 papers in training set
Top 0.1%
3.1%
6
Molecular and Cellular Biology
○ 47 papers in training set
Top 0.2%
3.1%
Similar papers in this journal
7
Theranostics
● 37 papers in training set
Top 0.2%
2.7%
8
Oncogenesis
○ 12 papers in training set
Top 0.1%
2.6%
9
PLOS ONE
● 5266 papers in training set
Top 39%
2.6%
10
Nature Communications
○ 5641 papers in training set
Top 39%
2.4%
11
Cancer Gene Therapy
○ 11 papers in training set
Top 0.1%
2.4%
12
Cancer Research
● 130 papers in training set
Top 2%
2.4%
13
Cell Death & Disease
147 papers in training set
Top 1%
2.4%
14
Scientific Reports
○ 3612 papers in training set
Top 43%
2.4%
15
Molecular Cancer Research
● 49 papers in training set
Top 0.5%
2.1%
16
Cancer Letters
○ 35 papers in training set
Top 0.4%
2.1%
50% of probability mass above
17
iScience
○ 1154 papers in training set
Top 18%
1.7%
18
FEBS Open Bio
○ 31 papers in training set
Top 0.3%
1.7%
19
Proceedings of the National Academy of Sciences
● 2444 papers in training set
Top 29%
1.7%
20
Acta Biochimica et Biophysica Sinica
● 23 papers in training set
Top 0.3%
1.5%
21
Molecular Cancer
○ 16 papers in training set
Top 0.1%
1.4%
22
Communications Biology
○ 993 papers in training set
Top 18%
1.4%
23
Cell Reports
○ 1498 papers in training set
Top 22%
1.3%
24
Frontiers in Oncology
○ 103 papers in training set
Top 2%
1.3%
25
International Journal of Molecular Sciences
○ 494 papers in training set
Top 10%
1.3%
26
The EMBO Journal
○ 309 papers in training set
Top 5%
1.1%
27
Molecular Oncology
○ 55 papers in training set
Top 1%
1.1%
28
Cell Communication and Signaling
○ 51 papers in training set
Top 0.9%
1.0%
29
Biomedicines
○ 67 papers in training set
Top 2%
1.0%
30
Cancers
○ 213 papers in training set
Top 4%
1.0%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.